Axa S.A. Has $172.71 Million Position in AbbVie Inc. (NYSE:ABBV)

Axa S.A. increased its holdings in AbbVie Inc. (NYSE:ABBV) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 971,893 shares of the company’s stock after purchasing an additional 125,568 shares during the period. Axa S.A. owned approximately 0.05% of AbbVie worth $172,705,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Accredited Wealth Management LLC acquired a new position in shares of AbbVie in the 4th quarter worth approximately $109,000. Advanced Portfolio Management LLC bought a new stake in AbbVie in the fourth quarter valued at $1,341,000. Alaethes Wealth LLC raised its stake in AbbVie by 1.5% during the fourth quarter. Alaethes Wealth LLC now owns 8,974 shares of the company’s stock worth $1,595,000 after acquiring an additional 131 shares in the last quarter. 1248 Management LLC bought a new position in shares of AbbVie during the fourth quarter valued at $1,212,000. Finally, 4WEALTH Advisors Inc. acquired a new stake in shares of AbbVie in the 4th quarter valued at $592,000. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 18,944 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the transaction, the senior vice president now owns 11,496 shares in the company, valued at approximately $2,338,401.36. This represents a 62.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the sale, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,471 shares of company stock valued at $23,426,451. Company insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of a number of recent analyst reports. Evercore ISI increased their target price on shares of AbbVie from $204.00 to $205.00 and gave the stock an “outperform” rating in a research report on Monday, April 28th. UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. The Goldman Sachs Group restated a “neutral” rating and set a $194.00 price target on shares of AbbVie in a research report on Tuesday, April 8th. Bank of America lifted their price objective on AbbVie from $200.00 to $223.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Finally, Guggenheim increased their target price on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a report on Tuesday. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $211.41.

AbbVie Price Performance

Shares of ABBV opened at $198.62 on Friday. The stock has a market cap of $351.35 billion, a P/E ratio of 82.76, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $218.66. The stock’s 50-day moving average price is $196.14 and its two-hundred day moving average price is $187.25. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The business had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same quarter last year, the firm earned $2.31 EPS. AbbVie’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s payout ratio is presently 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.